Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$41.01 USD
+0.64 (1.59%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $41.02 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XENE 41.01 +0.64(1.59%)
Will XENE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XENE
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
Other News for XENE
Xenon Pharmaceuticals: Q2 Earnings Snapshot
Xenon Reports Q2 2024 Financial Results and Business Update
Robust Financials and Promising Clinical Trials Bolster Xenon Pharma’s Buy Rating
XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024
TD Cowen Keeps Their Buy Rating on Xenon (XENE)